The United Kingdom and the United States have agreed to a landmark trade agreement that will preserve zero tariffs on UK medicine shipments entering the US market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has agreed to increase expenditure on drugs through the NHS. This move guarantees that duties on these key exports will be held at nothing for a timeframe of the next three years.
This agreement comes after earlier statements to hike import taxes on branded pharmaceutical products, with increases floated reaching one hundred percent.
"This arrangement between the UK reinforces the global environment for innovative medicines and brings long-overdue balance to U.S.–U.K. pharmaceutical trade," a release said.
Trade Significance
Pharmaceuticals represent one of the UK's largest export categories to the US, which is clearly the primary buyer for major British pharmaceutical firms.
Export figures indicate that in the one-year period to the end of September, the UK shipped drugs totaling billions to the US. This amount represented nearly one-fifth of total UK exports in that timeframe.
"This agreement safeguards work, increases investment and facilitates the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary stated.
Key British Pledges
The agreement includes several specific pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a goal to increase total public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must pay back to the NHS to control costs will be capped at fifteen percent. In the past, refunds were more than twenty percent.
Recent Tensions
This agreement takes place against a long-running tension between the drug companies and the ministers over drug pricing and regulatory access.
This friction were intensified by claims that American customers were charged a premium for the equivalent treatments than consumers in the Britain and the EU.
Recently, several significant manufacturing plans in the UK have been paused or abandoned, while substantial expansions have been announced toward projects in the United States.
A senior figure acknowledged that the NHS needed to spend more on drugs, noting that its expenditure on drugs had decreased as a proportion of its total funding over the last ten years.
